Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $10.3 million.

  • Allogene Therapeutics' Other Non-Current Assets changed 0.0% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $10.3 million for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Other Non-Current Assets is $10.3 million, which was down 0.0% from $10.3 million recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Other Non-Current Assets high stood at $10.3 million for Q4 2021, and its period low was $9.4 million during Q1 2021.
  • For the 5-year period, Allogene Therapeutics' Other Non-Current Assets averaged around $10.2 million, with its median value being $10.3 million (2021).
  • Over the last 5 years, Allogene Therapeutics' Other Non-Current Assets had its largest YoY gain of 11979.53% in 2021, and its largest YoY loss of 0.0% in 2021.
  • Allogene Therapeutics' Other Non-Current Assets (Quarter) stood at $10.3 million in 2021, then changed by 0.0% to $10.3 million in 2022, then changed by 0.0% to $10.3 million in 2023, then changed by 0.0% to $10.3 million in 2024, then changed by 0.0% to $10.3 million in 2025.
  • Its Other Non-Current Assets stands at $10.3 million for Q3 2025, versus $10.3 million for Q2 2025 and $10.3 million for Q1 2025.